Today, during remarks to families of children with life threatening diseases, Representative Kathy Hochul (NY-26) offered new hope. The Faster Access to Specialized Treatments (FAST) Act is a bipartisan proposal to expedite the Food and Drug Administration (FDA) approval process for new treatments for diseases like Duchenne Muscular Dystrophy, Alzheimer's, and Parkinson's.
"After hearing about children like Suneel fighting Duchenne Muscular Dystrophy as well as other individuals facing incurable diseases, I cosponsored the FAST Act. The current FDA approval process of drugs to treat incurable diseases simply takes too long, leaving many with debilitating conditions waiting perilously for a promising new treatment. The FAST Act has the potential to save lives. That is why I have been a strong supporter of this legislation and will continue to fight for its passage and implementation," Rep. Hochul said.
"Suneel's Light has been a strong supporter of this legislation that will allow innovative treatments for patients suffering from serious or life-threatening conditions to have potential treatments much sooner than in the past and we applaud and thank Congresswoman Kathy Hochul for her support and co-sponsorship of this bill," said David Korzak, President of Suneel's Light.
Cosponsored by Rep. Hochul, the FAST Act will allow experimental medications and treatments to be accelerated through the FDA approval process, giving patients of incurable diseases access to such treatments more quickly.
At the Hauptman Woodward Medical Research Institute, Rep. Hochul was joined by David Korzak, President of Suneel's Light; George Hajduczok, Chief Science Officer of Suneel's Light; and families of children afflicted with Duchenne Muscular Dystrophy.
Suneel's Light, a nonprofit organization committed to funding research for Duchenne Muscular Dystrophy, is named for Suneel Ram, a 15-year boy battling Duchene Muscular Dystrophy.